JP6501756B2 - 細菌人工染色体 - Google Patents

細菌人工染色体 Download PDF

Info

Publication number
JP6501756B2
JP6501756B2 JP2016509489A JP2016509489A JP6501756B2 JP 6501756 B2 JP6501756 B2 JP 6501756B2 JP 2016509489 A JP2016509489 A JP 2016509489A JP 2016509489 A JP2016509489 A JP 2016509489A JP 6501756 B2 JP6501756 B2 JP 6501756B2
Authority
JP
Japan
Prior art keywords
cdna
virus
rna
viral
bac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016509489A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518132A (ja
Inventor
ダルメイア，カイ
ネイツ，ヨハン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Publication of JP2016518132A publication Critical patent/JP2016518132A/ja
Application granted granted Critical
Publication of JP6501756B2 publication Critical patent/JP6501756B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2016509489A 2013-04-26 2014-04-25 細菌人工染色体 Active JP6501756B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1307528.8 2013-04-26
GBGB1307528.8A GB201307528D0 (en) 2013-04-26 2013-04-26 Bacterial artificial chromosomes
PCT/EP2014/058459 WO2014174078A1 (en) 2013-04-26 2014-04-25 Bacterial artificial chromosomes

Publications (2)

Publication Number Publication Date
JP2016518132A JP2016518132A (ja) 2016-06-23
JP6501756B2 true JP6501756B2 (ja) 2019-04-17

Family

ID=48626864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509489A Active JP6501756B2 (ja) 2013-04-26 2014-04-25 細菌人工染色体

Country Status (17)

Country Link
US (2) US10076564B2 (enExample)
EP (2) EP2989205B1 (enExample)
JP (1) JP6501756B2 (enExample)
KR (1) KR102170609B1 (enExample)
CN (2) CN120249337A (enExample)
AU (1) AU2014259354B2 (enExample)
BR (1) BR112015026531B1 (enExample)
DK (1) DK2989205T3 (enExample)
ES (1) ES2718187T3 (enExample)
GB (1) GB201307528D0 (enExample)
HU (1) HUE042886T2 (enExample)
PL (1) PL2989205T3 (enExample)
PT (1) PT2989205T (enExample)
SI (1) SI2989205T1 (enExample)
TR (1) TR201904215T4 (enExample)
WO (1) WO2014174078A1 (enExample)
ZA (1) ZA201507795B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201716307D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Chimeric yellow fever zika virus strain
GB201716254D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
US11254953B2 (en) * 2018-04-18 2022-02-22 Utah State University Compositions and methods for zika virus characterization and vaccine development
GB201814563D0 (en) 2018-09-07 2018-10-24 Univ Leuven Kath Chimeric flavivirus lyssavirus vaccines
BR112021020325A2 (pt) 2019-04-10 2021-12-14 Univ Leuven Kath Vírus quimérico zika-encefalite japonesa
WO2021048003A1 (en) 2019-09-13 2021-03-18 Katholieke Universiteit Leuven Chimeric filovirus vaccines
US20220378903A1 (en) 2019-09-13 2022-12-01 Katholieke Universiteit Leuven Lassavirus vaccines
WO2021058722A1 (en) 2019-09-25 2021-04-01 Katholieke Universiteit Leuven Large vectors and methods for high-yield production
JP2023516149A (ja) * 2020-02-27 2023-04-18 カソリーク ユニバーシテイト ルーバン コロナウイルスワクチン
WO2025012350A1 (en) * 2023-07-11 2025-01-16 Virovet Nv Vectors expressing attenuated rna virus of the family arteriviridae and uses thereof
WO2025171062A1 (en) * 2024-02-06 2025-08-14 The Regents Of The University Of California iMODULON GENE CLUSTERS AND METHODS TO IDENTIFY AND USE SAME

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665600A (en) 1991-09-18 1997-09-09 Research Corporation Technologies, Inc. Pichia pastoris linear plasmids and DNA fragments thereof
US5866404A (en) 1995-12-06 1999-02-02 Yale University Yeast-bacteria shuttle vector
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US5874259A (en) * 1997-11-21 1999-02-23 Wisconsin Alumni Research Foundation Conditionally amplifiable BAC vector
US6573090B1 (en) 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
US6472177B1 (en) 2001-04-23 2002-10-29 Wisconsin Alumni Research Foundation Expression vector with dual control of replication and transcription
US6864087B2 (en) 2001-07-31 2005-03-08 Wisconsin Alumni Research Foundation Method for converting single-copy BAC vectors to conditional high-copy pBAC/oriHC vectors
AU2002367130A1 (en) 2001-12-25 2003-07-15 Evec Incorporated Double-stranded cyclic dna capable of proliferating as artificial e. coli chromosome
AU2003275416A1 (en) 2002-10-04 2004-05-04 Embiosis Pharmaceuticals Compatible host/vector systems for expression of dna
US20070036827A1 (en) 2003-10-29 2007-02-15 The University Of Queensland West nile virus vaccine
US20050214838A1 (en) 2004-03-10 2005-09-29 Waclaw Szybalski Methods for mapping and sequencing nucleic acids
WO2009053988A1 (en) 2007-10-25 2009-04-30 Ramot At Tel-Aviv University Ltd. Production of bac vectors carrying viral genomes
CN101864442A (zh) * 2010-05-19 2010-10-20 江苏省农业科学院 重组火鸡疱疹病毒细菌人工染色体转移载体

Also Published As

Publication number Publication date
DK2989205T3 (en) 2019-04-23
EP2989205A1 (en) 2016-03-02
WO2014174078A1 (en) 2014-10-30
SI2989205T1 (sl) 2019-05-31
US20160206723A1 (en) 2016-07-21
KR20160003032A (ko) 2016-01-08
TR201904215T4 (tr) 2019-04-22
BR112015026531B1 (pt) 2023-02-07
EP3540065A1 (en) 2019-09-18
GB201307528D0 (en) 2013-06-12
US10076564B2 (en) 2018-09-18
AU2014259354A1 (en) 2015-11-05
HUE042886T2 (hu) 2019-07-29
PT2989205T (pt) 2019-04-23
EP2989205B1 (en) 2019-01-02
CN105229153A (zh) 2016-01-06
ZA201507795B (en) 2019-07-31
AU2014259354B2 (en) 2020-02-27
CN120249337A (zh) 2025-07-04
KR102170609B1 (ko) 2020-10-28
US20190111125A1 (en) 2019-04-18
PL2989205T3 (pl) 2019-06-28
BR112015026531A2 (enExample) 2017-09-05
JP2016518132A (ja) 2016-06-23
ES2718187T3 (es) 2019-06-28

Similar Documents

Publication Publication Date Title
JP6501756B2 (ja) 細菌人工染色体
KR20190016032A (ko) 백신 벡터로서 3개의 세그먼트를 가진 피친드 바이러스
EP2970981B1 (en) Recombinant rsv with silent mutations, vaccines, and methods related thereto
JP5908948B2 (ja) レオウイルス科のウイルスのワクチン用ウイルス株を製造する方法
CA3181193A1 (en) Rna replicon for versatile and efficient gene expression
US20060280757A1 (en) Flavivirus vaccine delivery system
Nickols et al. Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice
AU2005279303B2 (en) Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
EP4265631A2 (en) Live-attenuated flaviruses with heterologous antigens
JP2019535291A (ja) プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン
US20230203536A1 (en) Coronavirus rna replicons and use thereof as vaccines
JP2011510672A (ja) ワクチンとして使用するための、カプシドタンパク質中に欠失を含むフラビウイルス科突然変異体
AU2004245578B2 (en) Flavivirus replicon packaging system
EP3691680A1 (en) Chimeric yellow fever zika virus strain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190319

R150 Certificate of patent or registration of utility model

Ref document number: 6501756

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250